D
Diane Baker
Researcher at Charité
Publications - 3
Citations - 996
Diane Baker is an academic researcher from Charité. The author has contributed to research in topics: Ligelizumab & Omalizumab. The author has an hindex of 3, co-authored 3 publications receiving 705 citations.
Papers
More filters
Journal ArticleDOI
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
Torsten Zuberbier,Werner Aberer,Riccardo Asero,A H Abdul Latiff,Diane Baker,Barbara Ballmer-Weber,Jonathan A. Bernstein,Carsten Bindslev-Jensen,Zenon Brzoza,R Buense Bedrikow,G.W. Canonica,Martin K. Church,Timothy J. Craig,I V Danilycheva,Corinna Dressler,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,C. Katelaris,Emek Kocatürk,Kanokvalai Kulthanan,D. Larenas-Linnemann,Tabi A. Leslie,Markus Magerl,P. Mathelier-Fusade,R. Y. Meshkova,Martin Metz,Alexander Nast,Eustachio Nettis,Hanneke Oude-Elberink,Stefanie Rosumeck,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Christian Vestergaard,Bettina Wedi,Ricardo Niklas Werner,Zuotao Zhao,Marcus Maurer +48 more
TL;DR: In this paper, an evidence-and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.
Journal ArticleDOI
Ligelizumab for Chronic Spontaneous Urticaria
Marcus Maurer,Ana M Gimenez-Arnau,Gordon L Sussman,Martin Metz,Diane Baker,Andrea Bauer,Jonathan A. Bernstein,Randolf Brehler,Chia-Yu Chu,Wen-Hung Chung,I V Danilycheva,Clive Grattan,Jacques Hébert,Constance H. Katelaris,Michael Makris,R. Y. Meshkova,Sinisa Savic,Rodney Sinclair,Karl Sitz,Petra Staubach,Bettina Wedi,Jurgen Loffler,Avantika Barve,Kenneth Kobayashi,Eva Hua,Thomas Severin,Reinhold Janocha +26 more
TL;DR: A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelIZumab therapy of 72 mg or 240 mg than with omalizumab or placebo.
Journal ArticleDOI
EAACI/GA2LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria — konsentierte, deutschsprachige Übersetzung
Torsten Zuberbier,Torsten Zuberbier,Werner Aberer,Riccardo Asero,Amir Hamzah Abdul Latiff,Diane Baker,Barbara Ballmer-Weber,Jonathan A. Bernstein,Carsten Bindslev-Jensen,Zenon Brzoza,Roberta Buense Bedrikow,Giorgio Walter Canonica,Martin K. Church,Timothy J. Craig,I V Danilycheva,Corinna Dressler,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,Constance H. Katelaris,Emek Kocatürk,Kanokvalai Kulthanan,Désirée Larenas-Linnemann,Tabi A. Leslie,M. Magerl,P. Mathelier-Fusade,Raisa Meshkova,Martin Metz,Alexander Nast,Eustachio Nettis,Hanneke Oude-Elberink,Stefanie Rosumeck,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Christian Vestergaard,Bettina Wedi,Ricardo Niklas Werner,Zuotao Zhao,Marcus Maurer,Randolf Brehler,Knut Brockow,Joachim W. Fluhr,Jürgen Grabbe,Eckard Hamelmann,Karin Hartmann,Thilo Jakob,Thilo Jakob,Hans F. Merk,Markus Ollert,Hagen Ott,Imke Reese,Franziska Ruëff,Thomas Werfel +63 more
TL;DR: Diese evidenz- and konsensbasierte Leitlinie wurde entsprechend den Methoden der Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE)-Arbeitsgruppen entwickelt and umfasst die Definition and Klassifikation der Urtikaria unter Berücksichtigung der jüngsten Fortschritte in der Identifik